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Interleukin-17A (IL-17A), the most widely studied member of the IL-17 cytokine family, is a cytokine which emerged to be critical
for host defense as well as in the pathogenesis of autoimmune disorders. Moreover, IL-17A is involved in the pathogenesis of
cardiovascular diseases, such as atherosclerosis and acute coronary syndrome and in the cardiovascular risk associated with
systemic immunological disorders. Consistent with this, we have recently shown that IL-17A increases human and murine platelet
response to ADP. In this study we expanded our previous observation and we describe for the first time an in vivo prothrombotic
effect of the cytokine. Our results show that IL-17A is synergic with a low FeCl
3
concentration in inducing carotid thrombus in rats
and suggest that the effect is likely related to a downregulation of CD39 vascular expression and hydrolyzing activity. Our findings
indicate that IL-17A might be an important molecule at the interface between hemostasis and inflammation.
“This paper is dedicated to the memory of Professor Alfredo Colonna”
1. Introduction
Increasing experimental and clinical evidence show that
thrombosis and atherosclerosis might be closely associated
with an inflammatory reaction [1]. Inflammation decreases
the activity of natural anticoagulant mechanisms, initiates
clotting, and impairs the fibrinolytic system. Indeed, proin-
flammatory molecules are involved in the activation and
migration of leukocytes to sites of vascular injury and
inflammation and may contribute to the release by activated
cells of prothrombotic factors which, in turn, may activate
platelets and other cell types [2, 3].
Recently, much attention has been driven on haemostatic
disorders observed in subjects affected by immunological
chronic inflammation, such as rheumatoid arthritis (RA),
multiple sclerosis (MS), and inflammatory bowel disease
(IBD) that may represent the cause of the increased car-
diovascular risk observed in these pathologies [4–6]. Mul-
tiple factors may be implicated. Circulating cytokines and
recruited inflammatory cells could cause endothelial activa-
tion and dysfunction leading toward a prothrombotic state
[7, 8].
Interleukin-17A (IL-17A) is the most widely studied
member of the IL-17 cytokine family. It is mainly produced
by T-helper (Th)-17 lymphocytes, and also by natural killer T
(NKT) cells, 𝛾𝛿 T cells (𝛾𝛿-17), cytotoxic CD8+ T cells (Tc17),
and neutrophils [9–11]. IL-17A is a proinflammatory cytokine
[12], highly produced in patients with chronic inflammatory
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diseases, such as RA, MS, and IBD [13–15]. IL-17A is also
involved in atherosclerosis [16]; furthermore, in humans a
positive correlation has also been found between circulating
IL-17A levels and acute coronary syndrome [17, 18]. These
findings have suggested that IL-17A might play a role in the
cardiovascular risk associated with systemic immunological
disorders. Recently, in the attempt of finding a link between
inflammatory markers and endothelial dysfunction, Marder
et al. [19] demonstrated that IL-17A is an inflammatory
marker that could be positively correlated with markers of
impaired vascular function in subjects affected by rheuma-
toid arthritis. Consistent with this, it has also been shown
that, on HUVEC, IL-17A reduces CD39 mRNA expression
and synergistically with tumour necrosis factor 𝛼 (TNF𝛼) it
is able to induce tissue factor (TF) expression and to down-
regulate thrombomodulin expression [20]. It is known that
arterial thrombosis is primarily caused by platelet adhesion to
the damaged vessel and activation [21]. Following activation,
endothelium loses its antithrombotic properties and platelets
may become activated [2]. Thus, IL-17A could activate
endothelial cells toward a prothrombotic state; however, up
to now there is no in vivo evidence for this. We have recently
demonstrated that IL-17A increases human and murine
platelet response to adenosine-5󸀠-diphosphate (ADP). In
vitro this effect is associated with an increased exposition
of P-selectin on platelet surface [22]. Since platelets are
primary involved in arterial thrombus formation [21] and an
increased platelet reactivity has been found associated with
several systemic immunological disorders where also IL-17A
is involved [6, 7, 23], here we sought to investigate the effect
of IL-17A on in vivo arterial thrombus formation.
2. Materials and Methods
2.1. Ferric Chloride-Induced Thrombosis. Male Wistar rats
(300–350 g; Harlan Nossan, Correzzana, MI, Italy) were
used for all experiments. Animals were kept under standard
conditions with food ad libitum andmaintained in a 12 h/12 h
light/dark cycle at 22 ± 1∘C. All the in vivo procedures
were in accordance with the Italian legislative decree (D.L.)
number 116 of January 27, 1992, and associates guidelines in
the European Communities Council Directive of November
24, 1986 (8676097ECC). All efforts were made to minimize
animal suffering and to reduce their number.
Rats were anaesthetized with urethane (10%wt/v;
10mL/kg ip.) and placed on a surgical table. An arterial
thrombus was induced by FeCl
3
application onto the surface
of the right carotid artery, as described by Kurz et al. [24].
The effect of topical application of IL-17A was also evaluated.
In brief, following surgery, a piece of filter paper (Whatman
n∘1, 3 × 5mm) soaked in 10 𝜇L of a solution of FeCl
3
(5%)
or in recombinant mouse IL-17A (100𝜇g/mL in HCl 4mM,
R&D System, Abingdon, UK) was applied onto the external
surface of the right carotid artery for 30 minutes. Afterward
the paper was removed and the vessel was left in situ for 60
minutes, to enable thrombus formation. In another set of
experiments, an IL-17A (100𝜇g/mL), or vehicle (HCl 4mM),
soaked filter paper was applied on the vessel for 30 minutes
before applying FeCl
3
(5%), as described above. At the end
of 60-minute period, a piece of about 2 cm in length of the
right carotid artery (and its contralateral) was excised and
weighed. Thrombus size was evaluated by the difference in
weight between the treated vessel and its contralateral.
2.2. Morphological Analysis. In another group of animals,
the experiment was performed as described above and a
segment (2 cm) of each treated vessel was excised, rinsed
in saline to remove the blood excess, and then fixed in
formalin (4% v/v; Carlo Erba, Italy) for 24 hours. Samples
were processed and embedded in paraffin. Sections (10 𝜇m
thick) were then stained with haematoxylin and eosin (Carlo
Erba, Italy) in order to be morphologically analyzed. In all
cases, a minimum of 5 sections per animal were analysed
by using a standard light microscope (×5 and ×10 objective).
Images were taken by a Leica DFC320 video camera (Leica,
Milan, Italy) connected to a Leica DM RB microscope using
the Leica Application Suite software V2.4.0.
2.3.Western Blot Analysis of CD39. In subsets of experiments,
following local treatment with IL-17A or with its vehicle (HCl
4mM) for 30 minutes, as described above, CD39 expression
was evaluated on carotid section homogenates by Western
blot analysis. For this purpose, following local treatment,
carotids were immediately frozen in liquid nitrogen before
being stored at −80∘C. On the day of analysis, tissues were
homogenized using liquid nitrogen in the following lysis
buffer: Tris-HCl pH 7.5, 50mM; NaCl, 150mM; sodium
orthovanadate, 1mM; 𝛽 glycerophosphate, 20mM; EDTA,
2mM; PMSF 1mM; leupeptin, 5 𝜇g/mL; aprotinin, 5 𝜇g/mL;
pepstatin, 5 𝜇g/mL. Protein concentration was determined
by the Bio-Rad protein assay kit (Bio-Rad, Italy). Protein
samples (35 𝜇g) were subjected to electrophoresis on an SDS
8% polyacrylamide gel and transferred onto a nitrocellulose
transfer membrane (Protran, Schleicher & Schuell, Ger-
many). The membranes were saturated by incubation with
nonfat dry milk (5%wt/v) in PBS supplemented with 0.1%
(v/v) Tween 20 (PBS-T) for 1 h at room temperature and then
incubated with a goatmonoclonal anti-CD39 antibody (A-16,
Santa Cruz, CA) (dilution 1 : 200), overnight at 4∘C. Succes-
sively, membranes were washed and then incubated with the
secondary antibody conjugated with horseradish peroxidase,
anti-goat IgG-HRP (dilution 1 : 2000, Dako Denmark), for
2 h at room temperature. Protein bands were detected using
the enhanced chemiluminescence (ECL) detection kit and
Image Quant 400GE Healthcare software (GE Healthcare,
Italy). Protein bands were quantified using GS 800 imaging
densitometer software (Biorad, Italy).
2.4. Enzyme Assay. On carotid section homogenates, ADP
hydrolyzing activity was evaluated using a modification of
the method described by Saucedo et al. [25]. The reaction
medium used to assay ADPase activity contained 120mM
NaCl, 5.0mMKCl, 60mM glucose, 5mMCaCl
2
, and 50mM
Tris-HCl buffer, pH 7.5 in a final volume of 200𝜇L. A
sample volume of 20𝜇L (10 𝜇g proteins) was added to the
reaction medium and preincubated for 10 minutes at 37∘C.
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The enzyme reaction was then started by the addition of
ADP at a final concentration of 2mM and incubated for
40 minutes at 37∘C. Controls were performed by adding
deionized H
2
O to each sample, instead of ADP. The reaction
was stopped by the addition of 200𝜇L of trichloroacetic acid
(TCA) 10%. Samples were then centrifuged at 3000 rpm ×
10min. As ameasure of ADPase activity, inorganic phosphate
(Pi) released was quantified by a colorimetric assay Sensolyte
assay kit (AnaSpec) and expressed as nmol Pi released per 𝜇g
of protein [26].
2.5. Statistical Analysis. Data were expressed as mean ± S.E.
and analysed by one way analysis of variance (ANOVA),
followed by Bonferroni’s test for multiple comparisons, or
by unpaired two-tailed Student’s t-test when appropriate. In
some cases, one-sample t-test was used to evaluate signifi-
cance against the hypothetical zero value. A value of 𝑃 < 0.05
was taken as significant.
3. Results and Discussion
The increased platelet reactivity, endothelial dysfunction, and
atherosclerotic plaques instability are common features of
subjects affected by systemic immunological inflammatory
diseases and might represent the cause of the increased car-
diovascular risk observed in these patients [1, 5, 23]. However,
which factors are primarily responsible for predisposing to
haemostasis disturbances and to cardiovascular events in
chronic autoimmune diseases is still unknown. Recently,
IL-17A, which is critically involved in the pathogenesis of
autoimmune diseases, has been claimed as a possible candi-
date to participate in endothelial dysfunction and increased
cardiovascular risk [19, 20]. On these bases, our work was
aimed at evaluating in vivo the effect of IL-17A in a model
of ferric chloride-induced arterial thrombosis. We found that
application of FeCl
3
(5%) caused an intravascular thrombus
of 1.10 ± 0.23mg (𝑛 = 9; 𝑃 < 0.01 one-sample t-test) whose
mass increased significantly (1.91 ± 0.23mg; 𝑛 = 8. 𝑃 <
0.01) when carotid was pretreated with IL-17A (100𝜇g/mL),
30 minutes before FeCl
3
application. Application of IL-17A
alone on the external surface of rat carotid artery generated
per se a small intravascular thrombus (0.42±0.17mg; 𝑛 = 10;
𝑃 < 0.05) whereas nonsignificant effects were observed after
vehicle exposure (0.1 ± 0.05mg; 𝑛 = 7) (Figure 1).
Morphological analysis of the vessel section evidenced
that the luminal surface of carotid sections from control was
covered by a continuous endothelium.Moreover the vascular
lumen was not characterized by aggregates (Figure 2(a)).
Interestingly, sections obtained from IL-17A plus FeCl
3
showed an occluding thrombus compared with IL-17A
(Figure 2(b)) or FeCl
3
(Figure 2(c)) treated carotids. Further-
more, the endothelium appeared damaged and vessel wall
thickness extremely reduced (Figure 2(d)).
It is known that arterial thrombosis is primarily caused by
platelet adhesion and activation to the damaged vessel [21].
Following activation, endothelium loses its antithrombotic
properties and platelets may become activated [2].Themodel
of FeCl
3
-induced thrombosis has been shown to involve
Th
ro
m
bu
s w
ei
gh
t (
m
g)
0.0
0.5
1.0
1.5
2.0
2.5
Vehicle
IL-17A
FeCl3
− −
−
+ +
−
− −
−
+ +
++
∗∗∗
##
∘
Figure 1: Effect of IL-17A on thrombus mass induced by FeCl
3
application on rat carotid artery. A filter paper soaked in FeCl
3
(5%)
or in recombinant mouse IL-17A (100𝜇g/mL) was applied onto the
external surface of the right carotid artery, for 30 minutes; afterward
the paper was removed and the vessel was left in situ for 60 minutes,
to enable thrombus formation. In another set of experiments, an IL-
17A (100 𝜇g/mL), or vehicle (HCl, 4mM), soaked filter paper was
applied onto the vessel for 30 minutes before applying FeCl
3
(5%).
At the end of 60-minute period, a piece of about 2 cm in length of the
right carotid artery and of its contralateral was excised and weighed.
Thrombus size was evaluated by the difference inweight between the
treated vessel and its contralateral. All controls were performed by
applying only vehicle (H
2
O or HCl 4mM). ##𝑃 < 0.01 versus FeCl
3
,
∗∗∗
𝑃 < 0.001 versus IL-17A, and ∘𝑃 < 0.05 versus vehicle (one way
ANOVA followed by Bonferroni’s test; 𝑛 = 8–10).
platelets and several components of haemostasis [27], includ-
ing TF [28].
CD39/ATP diphosphohydrolase (ATPDase) is largely
expressed on vascular endothelial cells and by converting
ATP andADP tomonophosphate form (AMP) it represents a
key modulator of vascular haemostasis and thrombogenesis.
The loss of CD39 on activated endothelial cells causes
platelet sequestration and TF upregulation, key events for
thrombogenesis [29]. Nonetheless, CD39 also may offer pro-
tection against myocardial ischemia-reperfusion injury since
it promotes ADP degradation and thus favours, in tandem
with CD73 (ecto-5󸀠-nucleotidase), adenosine accumulation
that represents a cardiovascular protective molecule [30]. It
was shown that mice lacking CD39 had vascular features of
a prethrombotic state, characterized by fibrin deposition in
several vascular beds [31]. Recently, it has been demonstrated
that IL-17A reduces CD39 mRNA expression in human
endothelial cells in vitro and, at the same time, it increases
TF expression [20]. On these bases, and considering that
CD39 plays a crucial role in maintaining the endothelium
antithrombotic properties, we analysed its expression and
its ADP hydrolyzing activity on rat carotid artery following
the in vivo exposure to IL-17A. Results obtained show that
following the application of IL-17A on carotid surface the
expression of CD39 was significantly reduced compared with
the application of the only vehicle (HCl, 4mM) (Figure 3).
Concomitantly, ADP hydrolyzing activity was also reduced as
demonstrated by a reduced inorganic phosphate production,
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Figure 2: Photomicrographs showing hematoxylin and eosin histologic cross sections of carotid arteries following local treatment as
described in themethod section (magnification×50). (a)Vehicle (HCl 4mM); (b) IL-17A (100𝜇g/mL); (c) vehicle (HCl 4mM) plusFeCl
3
(5%);
and (d) IL-17A and FeCl
3
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Figure 3: (a) Representative results ofWestern blot analyses of CD39 expression on rat carotids treated for 30minutes with vehicle or IL-17A.
(b) Densitometric analysis of Western blots; O.D. (optical density) normalized against 𝛽-actin. ∗𝑃 < 0.05 versus vehicle (Student’s t-test;
𝑛 = 3).
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Figure 4: Quantification of inorganic phosphates (Pi) produced by
rat carotid homogenates treated with vehicle or IL-17A. Pi produced
was evaluated as measure of ADP hydrolyzing activity (for details,
see method section). ∗𝑃 < 0.05 versus vehicle (Student’s t-test; 𝑛 =
3).
following incubation with ADP, from IL17A treated carotids
compared to vehicle (Figure 4).Thus, through the downregu-
lation of CD39, IL-17Amight contribute to priming the vessel
for the effect of a minimal FeCl
3
concentration.
Our hypothesis would be consistent with the observation
that IL-17A does not cause per se an intra-arterial occlusive
thrombus, but it would induce those endothelial features
peculiar to a prothrombotic state. Indeed, the lack of ADP
hydrolysis due to CD39 downregulation on endothelial cells
would not be a stimulus for thrombogenesis but, most likely,
for the increase of platelet aggregates at the site of vascular
injury and this would facilitate the effect of a thrombotic
agent.
4. Conclusion
Our results give for the first time an in vivo evidence for
a prothrombotic effect of IL-17A that is likely related to
a downregulation of CD39 expression and activity in the
vascular system. Accordingly with our previous results that
demonstrated in vitro the effects of this cytokine on human
and murine platelets [22], in this study we suggest that this
cytokine might be an important molecule at the interface
between haemostasis and inflammation. Intriguingly, the
mechanistic bases of prothrombotic effect of IL-17A need
further investigation.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This work was supported by the ItalianMinistery of Research
(MIUR; 2008P9MR7YPRIN 2008).The authors would like to
thankDr.Antonio Baiano and alsoMrGiovanni Esposito and
Mr Angelo Russo for animal care and technical assistance.
References
[1] J. Frostegard, “Atherosclerosis in patients with autoimmune
disorders,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 25, no. 9, pp. 1776–1785, 2005.
[2] C. Cicala and G. Cirino, “Linkage between inflammation and
coagulation: an update on the molecular basis of the crosstalk,”
Life Sciences, vol. 62, no. 20, pp. 1817–1824, 1998.
[3] S. Strukova, “Blood coagulation-dependent inflammation. Co-
agulation-dependent inflammation and inflammation-depend-
ent thrombosis,” Frontiers in Bioscience, vol. 11, no. 1, pp. 59–80,
2006.
[4] J. P. Fa¨gerstam, P. A. Whiss, M. Stro¨m, and R. G. Andersson,
“Expression of platelet P-selectin and detection of soluble P-
selectin, NPY and RANTES in patients with inflammatory
bowel disease,” Inflammation Research, vol. 49, no. 9, pp. 466–
472, 2000.
[5] A. Mameli, D. Barcellona, and F. Marongiu, “Rheumatoid ar-
thritis and thrombosis,” Clinical and Experimental Rheumatol-
ogy, vol. 27, no. 5, pp. 846–855, 2009.
[6] P. A. Mac Mullan, A. J. Peace, A. M. Madigan, A. F. Tedesco, D.
Kenny, and G. M. McCarthy, “Platelet hyper-reactivity in active
inflammatory arthritis is unique to the adenosine diphosphate
pathway: a novel finding and potential therapeutic target,”
Rheumatology, vol. 49, no. 2, pp. 240–245, 2009.
[7] A. T. Nurden, “Platelets, inflammation and tissue regeneration,”
Thrombosis and Haemostasis, vol. 105, supplement 1, pp. S13–
S33, 2011.
[8] B. Engelmann and S. Massberg, “Thrombosis as an intravascu-
lar effector of innate immunity,” Nature Reviews Immunology,
vol. 13, no. 1, pp. 34–45, 2013.
[9] F. D’Acquisto, F. Maione, and M. Pederzoli-Ribeil, “From IL-15
to IL-33: the never-ending list of new players in inflammation.
Is it time to forget the humble aspirin and move ahead?”
Biochemical Pharmacology, vol. 79, no. 4, pp. 525–534, 2010.
[10] R. M. Onishi and S. L. Gaffen, “Interleukin-17 and its tar-
get genes: mechanisms of interleukin-17 function in disease,”
Immunology, vol. 129, no. 3, pp. 311–321, 2010.
[11] Y. Iwakura, H. Ishigame, S. Saijo, and S. Nakae, “Functional
specialization of interleukin-17 familymembers,” Immunity, vol.
34, no. 2, pp. 149–162, 2011.
[12] F. Maione, N. Paschalidis, N. Mascolo, N. Dufton, M. Perretti,
and F. D’Acquisto, “Interleukin 17 sustains rather than induces
inflammation,” Biochemical Pharmacology, vol. 77, no. 5, pp.
878–887, 2009.
[13] X. Q. Chen, Y. C. Yu, H. H. Deng et al., “Plasma IL-17A is
increased in new-onset SLE patients and associatedwith disease
activity,” Journal of Clinical Immunology, vol. 30, no. 2, pp. 221–
225, 2010.
[14] J. Leipe, M. Grunke, C. Dechant et al., “Role of Th17 cells in
human autoimmune arthritis,”Arthritis & Rheumatism, vol. 62,
no. 10, pp. 2876–2885, 2010.
[15] X.-F. Zhao, H.-F. Pan, H. Yuan et al., “Increased serum interleu-
kin 17 in patientswith systemic lupus erythematosus,”Molecular
Biology Reports, vol. 37, no. 1, pp. 81–85, 2010.
6 International Journal of Inflammation
[16] E. Smith, K. M. Prasad, M. Butcher et al., “Blockade of interleu-
kin-17A results in reduced atherosclerosis in apolipoprotein E-
deficient mice,” Circulation, vol. 121, no. 15, pp. 1746–1755, 2010.
[17] X. Cheng, X. Yu, Y.-J. Ding et al., “The Th17/Treg imbalance in
patients with acute coronary syndrome,” Clinical Immunology,
vol. 127, no. 1, pp. 89–97, 2009.
[18] R. E. Eid, D. A. Rao, J. Zhou et al., “Interleukin-17 and interfer-
on-𝛾 are produced concomitantly by human coronary artery-
infiltrating T cells and act synergistically on vascular smooth
muscle cells,” Circulation, vol. 119, no. 10, pp. 1424–1432, 2009.
[19] W. Marder, S. Khalatbari, J. D. Myles et al., “Interleukin 17 as
a novel predictor of vascular function in rheumatoid arthritis,”
Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1550–1555,
2011.
[20] A. Hot, V. Lenief, and P. Miossec, “Combination of IL-17 and
TNF𝛼 induces a pro-inflammatory, pro-coagulant and pro-
thrombotic phenotype in human endothelial cells,”Annals of the
Rheumatic Diseases, vol. 71, no. 5, pp. 768–776, 2012.
[21] Z. M. Ruggeri, “Platelet interactions with vessel wall com-
ponents during thrombogenesis,” Blood Cells, Molecules, and
Diseases, vol. 36, no. 2, pp. 145–147, 2006.
[22] F. Maione, C. Cicala, E. Liverani, N. Mascolo, M. Perretti, and
F. D’Acquisto, “IL-17A increases ADP-induced platelet aggre-
gation,” Biochemical and Biophysical Research Communications,
vol. 408, no. 4, pp. 658–662, 2011.
[23] J. Garbaraviciene, S. Diehl, D. Varwig et al., “Platelet P-selectin
reflects a state of cutaneous inflammation: possible application
to monitor treatment efficacy in psoriasis,” Experimental Der-
matology, vol. 19, no. 8, pp. 736–741, 2010.
[24] K. D. Kurz, B. W. Main, and G. E. Sandusky, “Rat model
of arterial thrombosis induced by ferric chloride,” Thrombosis
Research, vol. 60, no. 4, pp. 269–280, 1990.
[25] E.M. Saucedo, R. S. Pereira, G.M. Barbosa et al., “Enzymes that
hydrolyze adenine nucleotides in lymphocytes and platelets of
immunosuppressed rats,” Biomedicine & Pharmacotherapy, vol.
64, no. 6, pp. 437–440, 2010.
[26] K.-M. Chan, D. Delfert, and K. D. Junger, “A direct colorimetric
assay for Ca2+-stimulated ATPase activity,” Analytical Biochem-
istry, vol. 157, no. 2, pp. 375–380, 1986.
[27] R. J. Broersma, L. W. Kutcher, and E. F. Heminger, “The effect
of thrombin inhibition in a rat arterial thrombosis model,”
Thrombosis Research, vol. 64, no. 4, pp. 405–412, 1991.
[28] L. Wang, C. Miller, R. F. Swarthout, M. Rao, N. Mackman, and
M. B. Taubman, “Vascular smooth muscle-derived tissue factor
is critical for arterial thrombosis after ferric chloride-induced
injury,” Blood, vol. 113, no. 3, pp. 705–713, 2009.
[29] B. Atkinson, K. Dwyer, K. Enjyoji, and S. C. Robson, “Ecto-
nucleotidases of the CD39/NTPDase family modulate platelet
activation and thrombus formation: potential as therapeutic
targets,” Blood Cells, Molecules, and Diseases, vol. 36, no. 2, pp.
217–222, 2006.
[30] M. Cai, Z. M. Huttinger, H. He et al., “Transgenic over ex-
pression of ectonucleotide triphosphate diphosphohydrolase-1
protects against murine myocardial ischemic injury,” Journal of
Molecular and Cellular Cardiology, vol. 51, no. 6, pp. 927–935,
2011.
[31] K. Enjyoji, J. Se´vigny, Y. Lin et al., “Targeted disruption of
cd39/ATP diphosphohydrolase results in disordered hemostasis
and thromboregulation,”NatureMedicine, vol. 5, no. 9, pp. 1010–
1017, 1999.
